Literature DB >> 8698742

Carboplatin and cisplatin: are they equivalent in efficacy in "optimal residual" advanced ovarian cancer?

M Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8698742     DOI： 10.1007/bf01187154

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  8 in total

1.  Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.

Authors:  P F Conte; M Bruzzone; F Carnino; S Chiara; M Donadio; V Facchini; P Fioretti; G Foglia; A Gadducci; L Gallo
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

2.  Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.

Authors:  C Mangioni; G Bolis; S Pecorelli; K Bragman; A Epis; G Favalli; A Gambino; F Landoni; M Presti; W Torri
Journal:  J Natl Cancer Inst       Date:  1989-10-04       Impact factor: 13.506

3.  Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  K Swenerton; J Jeffrey; G Stuart; M Roy; G Krepart; J Carmichael; P Drouin; R Stanimir; G O'Connell; G MacLean
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

4.  Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

Authors:  D S Alberts; S Green; E V Hannigan; R O'Toole; D Stock-Novack; P Anderson; E A Surwit; V K Malvlya; W A Nahhas; C J Jolles
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

5.  Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.

Authors:  A E Taylor; E Wiltshaw; M E Gore; I Fryatt; C Fisher
Journal:  J Clin Oncol       Date:  1994-10       Impact factor: 44.544

Review 6.  Advanced ovarian cancer. Carboplatin versus cisplatin.

Authors:  J B Vermorken; W W ten Bokkel Huinink; E A Eisenhauer; G Favalli; D Belpomme; P F Conte; S B Kaye
Journal:  Ann Oncol       Date:  1993       Impact factor: 32.976

7.  Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.

Authors:  D F Bajorin; M F Sarosdy; D G Pfister; M Mazumdar; R J Motzer; H I Scher; N L Geller; W R Fair; H Herr; P Sogani
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

8.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

Authors: 
Journal:  BMJ       Date:  1991-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.